Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Inclusion Criteria: * Patients must have histological confirmation of breast carcinoma * Patients must have invasive breast cancer (IBC), confirmed according to international consensus criteria: * Onset: Rapid onset of breast erythema, edema, and/or peau d'orange, and/or warm breast, with or without an underlying breast mass * Duration: History of such findings no more than 6 months * Extent: Erythema occupying at least 1/3 of whole breast * Pathology: Pathologic confirmation of invasive carcinoma * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Patients must have negative HER2 expression on immunohistochemistry (IHC) (defined as 0 or 1+) or fluorescence in situ hybridization (FISH) analysis; if HER2 is 2+, negative HER2 expression must be confirmed by FISH (HER2/cep17 ration \< 2, and/or copy number less than 6); ER and PgR expression should be less than 10% * Patients have left ventricular ejection fraction (LVEF) \>= 50% by multigated acquisition scan (MUGA) or echocardiogram before study randomization * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L * Platelet count \>= 100 x 10\^9/L * Hemoglobin \>= 9.0 g/dL * Aspartate aminotransferase (AST) =\< 3.0 x upper limit of normal (ULN) * Alanine aminotransferase (ALT) =\< 3.0 x ULN * Alkaline phosphatase (ALP) =\< 2.5 x ULN * Total bilirubin =\< 1.5 x ULN * Creatinine (Cr) =\< 1.5 mg/dL x ULN * Creatinine clearance (CrCl) \>= 50 mL/min calculated by the Cockroft-Gault *…